Tracking kidney disease patients on new medications
NCT ID NCT07481084
Summary
This study aims to understand how patients with IgA nephropathy (a kidney disease) respond to two newer medications, iptacopan or atrasentan, in real-world clinical practice. It will follow 80 adult patients in China for 24 months to collect information on their health, treatment patterns, and kidney function outcomes. The goal is to gather practical knowledge about how these drugs work outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.